# Tiespectus PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/tiespectus

> The next catalyst for tiespectus, sponsored by Merck & Co., Inc. (MRK), is its topline data readout, Oct 2028 to Jan 2029.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | tiespectus |
| Codes | MK-8748, EYE201 |
| Sponsor | Merck & Co., Inc. (MRK) https://sec-api.dev/companies/mrk/catalysts |
| Indications | [Diabetic Retinopathy](https://sec-api.dev/indications/diabetic-retinopathy) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Oct 2028 to Jan 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Diabetic Retinopathy; Macular Edema.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07705555 (A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-10-31 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT07705555

### October 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Diabetic Retinopathy; Macular Edema.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07705555 (A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-10-31 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT07705555

### Nov 2028 to Feb 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Diabetic Retinopathy; Macular Edema.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07705607 (A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-30 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT07705607

### November 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Diabetic Retinopathy; Macular Edema.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07705607 (A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-30 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT07705607

## Same indication

- [Surabgene lomparvovec](https://sec-api.dev/pdufa/surabgene-lomparvovec) (ABBV)
- [Tarcocimab](https://sec-api.dev/pdufa/tarcocimab) (KOD)

Calendar months: [October 2028](https://sec-api.dev/fda-calendar/2028-10), [November 2028](https://sec-api.dev/fda-calendar/2028-11)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/tiespectus.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Tiespectus PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/tiespectus

```bibtex
@misc{secapidev_pdufa_tiespectus_20261116,
  title        = {Tiespectus PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/tiespectus}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_tiespectus_20261116","title":"Tiespectus PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/tiespectus","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
